MILREM-ROBOTICS
25.11.2021 09:02:10 CET | Business Wire | Press release
The iMUGS Consortium, in charge of a 32,6 MEUR project developing the European standard unmanned ground system (UGS), demonstrated how defence forces can use tactical 4G/5G communications networks and UGS’ equipped with ISR and signal intelligence payloads, jammers, acoustic sensors, and various other technology to conduct missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005387/en/
The demonstration that was performed in September in Latvia, was led by LMT, a member of the integrated Modular Unmanned Ground System (iMUGS) consortium, with the support of the project coordinator Milrem Robotics and featured an ensemble of different technology.
Latvian National Armed Forces used two Milrem Robotics’ THeMIS Unmanned Ground Vehicles (UGV) during two scenarios to display the benefits of teaming up manned units with unmanned systems.
One THeMIS UGV was equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT) provided by The Electronic Communications Office of Latvia, Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios (Tough SDR Vehicular), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The RWS integration was part of the demonstration, but not of the iMUGS project itself.
The second THeMIS, used as a mule for transporting the squad’s equipment, was equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular.
The units and UGVs used Bittium’s tactical communication network TAC WIN combined with LMT’s commercial 4G and a tactical 5G-SA bubble provided by Bittium and Cumucore.
In addition, Krauss-Maffei Wegmann’s (KMW) Dingo infantry mobility vehicle was used as the command centre from where UGVs were operated in Line of Sight (LOS) and Beyond the Line of Sight (BLOS) mode using Bittium’s SDR radios and to where the ISR and Signal Intelligence sensor feed was relayed and incorporated into LMT’s Battle Management System Viedsargs.
“The displayed scenarios showed that unmanned systems, enhanced with innovative communication systems and various defence technology, can be used for collecting and sharing tactical information, improve situational awareness, decrease troops physical load, and increase force protection,” explained Kuldar Väärsi, CEO of Milrem Robotics.
''For the first time ever, in a special network, a tactical network was connected with a stand-alone 5G network. This allowed communication between units and robots, as well as collecting information from sensors and placing this information into LMT’s Battle Management System "Viedsargs'','' said Ingmars Pukis, Vice President and Member of the Management Board of LMT.
Additional equipment used in the demonstration included: SRC Brasa's NATRIX UGV used for CASEVAC, high-speed First-Person View drone, Vertical Take-off, and Landing UAV STAR, and a gunshot detection and source recognition audio sensor by Riga Technical University (RTU).
The iMUGS project was launched in 2020 to develop a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems. Its goal is to standardize a Europe-wide ecosystem for ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will use an existing UGV – Milrem Robotics’ THeMIS – and a specific list of payloads.
The project’s progress is displayed during six demonstrations. „So far Milrem Robotics and LMT Innovations have set the bar very high. Which means we have some great things to wait for as the main results of the iMUGS projects are yet to be seen,“ said Martin Jõesaar from the Estonian Center for Defence Investments, the representative of the participating Member States in the iMUGS Project. The next demonstration will take place in Q1 of 2022 in Finland.
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Bittium, Diehl Defence, dotOcean, GMV Aerospace and Defence, Insta Advance, Krauss-Maffei Wegmann, Latvijas Mobilais Telefons (LMT), NEXTER Systems, Royal Military Academy of Belgium, Safran Electronics & Defense, Sol.One and Talgen Cybersecurity.
Watch the Demo 2 Scenarios here:
https://www.youtube.com/watch?v=-_iLCV3Ob2I
https://www.youtube.com/watch?v=HbK_ixrTuWU
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005387/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
